Study of Bulumtatug Fuvedotin for advanced triple-negative breast cancer
Part of Cancer, Skin clinical trials.
This study tests a new drug called bulumtatug fuvedotin for people with triple-negative breast cancer that has spread or come back. It's for those who have already tried certain other treatments, including a taxane and a specific type of antibody-drug conjugate.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have triple-negative breast cancer that has spread or come back after treatment.
- You have already been treated with a taxane chemotherapy and an antibody-drug conjugate that targets topoisomerase (like trastuzumab deruxtecan or sacituzumab govitecan).
- You have had no more than 3 prior chemotherapy regimens for advanced disease.
- You are willing to provide a sample of your tumor tissue from a past biopsy or have a new biopsy.
- You have not had treatment with certain other antibody-drug conjugates, like enfortumab vedotin or tisotumab vedotin.
- You are in generally good health (able to do daily activities, with adequate organ function).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 3 trial tests a combination of famitinib (a cancer drug that targets blood vessel growth) with immunotherapy drugs in people with newly diagnosed advanced triple-negative breast cancer that has spread or cannot be fully removed. It aims to improve how long patients live and how well the cancer responds.
This Phase 2 trial tests a treatment for people with triple-negative breast cancer that has come back or spread and has continued to progress despite earlier therapies. It may help by trying a new approach in patients who still have enough health to safely receive more treatment.
This trial tests a new immunotherapy drug (cadonilimab) combined with a chemotherapy (eribulin) against chemotherapy alone for triple-negative breast cancer that has come back or spread. If you receive the combination, the goal is to see if it helps control the cancer better or for longer.
This study tests a new combination of drugs—cromolyn, TQB2102, and panpulimab—for women with triple negative breast cancer that has not responded to previous immunotherapy. The goal is to see if this combination can shrink or slow the cancer and give you another treatment option.
This study tests a new drug combination (BL-B01D1 plus an immunotherapy) for people with advanced triple-negative breast cancer who have not had prior treatment for their advanced disease. The goal is to see if the combination works better at shrinking or controlling the cancer.
This study tests a new combination of two targeted drugs for advanced triple-negative breast cancer. It aims to see if the combination can help stop the cancer from growing, and it may be an option if you've already tried standard chemotherapy.
Hear when a new Triple Negative Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.